Skip to content
  • Facebook
  • Twitter
This translation is automatically provided by Google; please refer to the original English version for appropriate wording.
Take on Typhoid

Take on Typhoid

  • Home
  • Why Typhoid?
    • Typhoid & Related Salmonelloses
    • Global Research
    • Links & Resources
  • The Issues
    • Vaccines
    • WASH
    • Drug-Resistant Typhoid
    • Treatment
    • Diagnostics
    • Typhoid intestinal perforation
    • Related Issues
  • Resources & Tools
    • Talk About Typhoid
    • Global Policy
    • Country Tools
    • Infographics
    • Fact Sheets
    • TCV Cost-effectiveness
    • Share on Social
  • Blog & News
    • Blog
    • News
    • Publications
    • Newsletter
  • International Conference
    • Past Conferences
    • Conference Travel
  • About Us
    • About the Coalition against Typhoid
    • About the Typhoid Vaccine Acceleration Consortium

Huge turnout for typhoid vaccines in Mbire

Posted on June 7, 2021 by Eva Neumann
  • Children ages 6 months-15 years are receiving the typhoid conjugate vaccine as part of the Zimbabwe TCV campaign launch.
  • Villagers in Mbire district are appearing to receive the vaccine in mass quantities—eager to be relieved of the immense burden that typhoid cases have had in their community.

Post navigation

Zimbabwe launches typhoid vaccination campaign
68 typhoid fever cases recorded in Calabarzon

Newsletter Signup

Recent Posts

  • Humanly possible: The people making vaccine introductions a reality

  • L’humain au cœur de l’introduction des vaccins

  • Data collection in Cambodia: Ensuring high-quality data to support decision-making

  • Data collection in Burkina Faso: Coordinating local partners to gather data on typhoid burden

  • Climate change in Niger and its impact on community health

cat
685 West Baltimore Street, Room 480
Baltimore, MD 21201-1509
Coalition against Typhoid
2175 K Street, NW, Suite 400
Washington, DC 20037
© 2018. Coalition Against Typhoid. All Rights Reserved.
  • Contact Us
  • Privacy Policy
  • Facebook
  • Twitter
Top